Angiogenic factors and the endometrium following long term progestin only contraception

C.J. Lockwood, F. Schatz and G. Krikun
Department of Ob/Gyn, New Haven, CT, USA

Summary. Endometria from long term progestin only contraceptive-treated patients display abnormally enlarged blood vessels that are prone to bleeding as well as inflammation and possibly local diminution in blood flow. Such bleeding is also characterized by focal reductions in the expression of angiopoietin-1, a vessel stabilization and maturation agent, and excess production of the potent angiogenic agents, vascular endothelial growth factor and angiopoietin-2. In addition, tissue factor, the key initiator of hemostasis may play an angiogenic role either directly or via the activation of thrombin. This review article summarizes current findings related to the endometrial dysregulation of angiogenic/hemostatic agents following treatment with long term progestin only contraception. Studies in this area offer a promising avenue to alleviate abnormal uterine bleeding associated with this otherwise highly effective form of contraception.

Key words: Contraception, Uterine Bleeding, Angiogenesis, Endometrium

Long term progestin only contraception results in abnormal uterine bleeding

Abnormal uterine bleeding (AUB) is the leading indication for discontinuation of long-term, progestin-only contraceptives (LTPOCs) (Belsey, 1988; Su-Juan et al., 1994). These agents provide a highly practical solution to family planning needs in developed and developing countries (Archer et al., 1996; Fan and Su-Juan, 1996). While the biochemical processes underlying LTPOCs associated bleeding are not clearly understood, it is clear that the mechanisms involved diverge from the tight regulation of menstrual cycle-related endometrial hemostasis, angiogenesis and bleeding.

During the regular menstrual cycle, progesterone (P4) induces estradiol (E2)-primed human endometrial stromal cells (HESCs) to decidualize around blood vessels in the mid-luteal phase in preparation for the implanting blastocyst. Decidualized HESCs are ideally positioned to mitigate the risk of hemorrhage at this time, or to mediate menstruation in response to P4 withdrawal in non-fertile cycles (Lockwood and Schatz, 1996).

Following hormone withdrawal and menstruation, the functional endometrial layer is replenished by the sequential effects of E2 and P4. During menstruation, loss of the superficial endometrial layer produces gaping vessels from which endothelial cells sprout, and recruit pericytes to form capillaries and smooth muscle cells to form larger vessels (Smith, 1998). Peri-menstrual hypoxia is thought to initiate angiogenesis by inducing vascular endothelial cell growth factor (VEGF), the primary angiogenic agent, in endometrial stromal and epithelial cells (Popovici et al., 1999; Sharkey et al., 2000).

By contrast, LTPOC-associated AUB is spontaneous, focal and transient, with stable or elevated circulating P4 levels (Runic et al., 1997). Such AUB appears to be derived from structural changes in the vasculature resulting in dilated, superficial, thin walled “fragile” microvessels (Hickey et al., 1996, 1999; Rogers, 1996; Hickey et al., 1999; Runic et al., 2000). In addition to changes in the structural integrity of the microvessels, changes may also occur in support cells like the pericytes as demonstrated by the reduction in vascular smooth muscle α-actin expression in LTPOC-exposed endometrium (Hickey and Fraser, 2000; Hague et al., 2002). These observations strongly suggest that LTPOC treatment results in aberrant endometrial angiogenesis.

Recent reports (Rogers, 1996; Runic et al., 1997; Lebovic et al., 2000; Hague et al., 2002; Krikun et al., 2002) link LTPOC-associated AUB to aberrant expression of endometrial hemostatic and angiogenic factors. Below we review the current data on this subject.
Vascular endothelial growth factor expression following LTPOC

The human vascular endothelial growth factor (VEGF) gene contains 8 exons, 7 introns and a 14 kb coding region. Alternative exon splicing of a single VEGF gene produces 6 different isoforms. These include the predominant isoform VEGF165, as well as VEGF121, VEGF145, VEGF183, VEGF189 and VEGF 206 (Ferrara, 1999; Robinson and Stringer, 2001). The prominent VEGF isoforms expressed by the endometrium and by primary cultured endometrial stromal cells are VEGF165 and VEGF121 a nonheparin-binding acidic protein, which is freely diffusible (Torry et al., 1996; Ferrara, 1999; Robinson and Stringer, 2001). Binding of VEGF to the Flt-1 and KDR surface receptors activates their tyrosine kinase function resulting in enhanced endothelial cell proliferation, migration, vascular permeability, and protease activity (Ferrara, 1999). Flt-1 and KDR are restricted to endothelial cells, and cells of common embryonic origin (Ferrara, 1999). Binding to both receptors is required for maximal angiogenesis. Expression of Flt-1 in both quiescent and proliferating endothelial cells (Peters et al., 1993) suggests that VEGF regulates endothelial cell maintenance as well as angiogenesis.

Under normal physiological conditions, there appears to be a complex interplay between hormones and VEGF expression in the primate endometrium. While the VEGF promoter contains 3 half palindromic sites for the estrogen receptor, no progesterone receptor sites have been described (Tischer et al., 1991). There is conflicting data from different laboratories regarding the induction of VEGF expression in the endometrium during the menstrual cycle. Hence, while some reports indicate that VEGF-expression is enhanced in the secretory phase, others have found biphasic increases in the mid and late proliferative and secretory phases of the cycle (Shifren et al., 1996; Smith et al., 1996; Smith 1998, Charnock-Jones et al., 2000).

A study by Zhang et al. (1998) reported on the expression and localization of VEGF during the menstrual cycle. The authors reported that VEGF expression occurred predominantly in the endometrial epithelium and while weak in the proliferative phase, was strong in the secretory phase. VEGF expression in the stroma was weaker than in the glands and did not change throughout the cycle. Conversely, Torry and Torry reported that endometrial stromal cells display very intense foci of VEGF staining in particular during the proliferative phase of the cycle (Torry and Torry, 1997). Finally, a study by Hornung and coworkers reported that while endometrial VEGF expression displays diffusely positive messenger RNA and protein expression, glandular epithelium showed focal VEGF immunostaining at the apical surface (Hornung et al., 1998). The authors propose that VEGF is secreted apically into the gland lumina, and rather than playing an angiogenic role in the endometrium, it is potentially involved in influencing the nutrition and/or apposition of the developing blastocyst (Hornung et al., 1998).

Although physiological VEGF levels promote angiogenesis, over-expressed VEGF induces endothelial vascular “leakiness”, bleeding and perivascular ECM dissolution associated with pathological conditions. Indeed, Yokoyama and coworkers have shown that over-expression of VEGF, and 2 of its receptors were related to poor prognosis of patients with endometrial carcinomas (Yokoyama et al., 2000).

Alterations in the production or distribution of VEGF have been proposed to be related to LTPOC-induced AUB. One study demonstrated that the glandular and stromal VEGF staining indices were significantly higher in endometria following Norplant treatment than in untreated endometria, however, no correlation was found between the VEGF staining index following Norplant treatment and endometrial microvascular density (Lau et al., 1999). By contrast, in women treated with Implanon, only the stromal VEGF staining indices were found to be significantly elevated compared to controls and a positive correlation was observed between stromal-VEGF immunoreactivity and endothelial cell density (Charnock-Jones et al., 2000).

An in vitro study by Classen-Linke et al. demonstrated that the progestin medroxyprogesterone acetate (MPA) increased VEGF release in endometrial epithelial cell cultures (Classen-Linke et al., 2000). Interestingly, a recent study from our laboratory showed
that MPA did not alter secreted VEGF levels in cultured human endometrial epithelial cells or human endometrial stromal cells. Instead, the study demonstrated that the combined effects of excess thrombin and MPA resulted in the induced expression of VEGF in human endometrial stromal cells but the production of VEGF by glandular epithelial cells was not affected under these conditions (Lockwood et al., 2002). Hence, it is possible that in vivo, continued progestin exposure results in the production of other intermediate agents such as thrombin or the expression of other angiogenic agents (see angiopoietins, below) which either result in enhanced endometrial VEGF production or act in concert with VEGF leading to the aberrant angiogenic patterns observed in LTPOC users.

Angiopoietin expression following LTPOC

While VEGF has been identified as the primary vasculogenic and angiogenic factor, recently another family of proteins, the angiopoietins, has also been shown to be a key regulator of angiogenesis. Angiopoietin 1 (Ang-1) and angiopoietin 2 (Ang-2) are glycosylated, secreted proteins which have characteristic protein structures that contain coiled coil domains in the N-terminal portion and fibrinogen like domains in the C-terminal portion of the molecule (Suri et al., 1996; Maisonpierre et al., 1997). Ang-1 was mapped to the long arm of chromosome 8 while Ang-2 was mapped to the short arm of chromosome 8 (Cheung et al., 1998). The four members of this family (Ang-1 to 4) modulate angiogenesis by activating or blocking activation of their endothelial receptor Tie2, a surface receptor tyrosine kinase (Gale and Yancopoulos, 1999; Holash et al., 1999; Valenzuela et al., 1999). Ang-1 affects vascular integrity by acting at a later stage of vascular development than VEGF. Ang-1 always asserts its effects by activating Tie2 (Davis et al., 1996).

Transgenic Ang-1 and Tie2 knockout mice result in embryonic lethality associated with aberrant interactions between endothelial cells and their surrounding supporting cells (Suri et al., 1996). Moreover, transgenic over-expression of Ang-1 elicits marked pathological hypervascularization and regional varicosities (Suri et al., 1998) similar to that observed in LTPOC-exposed endometria.

Unlike the activating role of Ang-1, Ang-2 generally blocks Tie2 activation (Ward and Dumont, 2002). Recent studies have now suggested that Ang-2 has a dual function in the processes of postnatal angiogenesis and vascular remodeling and that Ang-2 signals are required for the proper development and function of the lymphatic vessels (Gale et al., 2002).

Consistent with the action of Ang-2 as a partial antagonist of Ang-1/Tie2 interactions, transgenic over-expression of Ang-2 results in embryonic lethality with a phenotype similar to mice lacking either Ang-1 or Tie2 (Maisonpierre, 1997). Ang-2 is expressed in areas undergoing vascular remodeling (Maisonpierre, 1997). Like VEGF, Ang-2 enhances vascular permeability. Both hypoxia and VEGF up-regulate Ang-2 expression in bovine microvascular endothelial cells (Oh et al., 1999). Thus, VEGF, Ang-1 and Ang-2 have complementary roles in vascular development and maintenance. While many studies have focused on the role of Ang-1 and Ang-2, murine Ang-3 and human Ang-4 have only recently been cloned and their function and localization is not yet well defined (Valenzuela et al., 1999).

Our group has shown that Ang-1 and Ang-2 are expressed in normal human endometrium. Specifically, immunohistochemical studies in the endometrium revealed that both secretory and proliferative endometrium displayed low intensity staining for Ang-1. The highest degree of staining occurred in the endometrium with low level staining in the stroma and in the glands (Krikun et al., 2002). Semi-quantitative RT-PCR studies with isolated stroma or endothelial cells however showed that Ang1 mRNA was only found in the stroma and not in the endothelial cells. We posit that the immuno-histochemical staining for Ang-1 in the endothelial cells results from binding to the receptor Tie-2 and not from synthesis by these cells.

By contrast, the immunohistochemical expression of Ang-2 and Tie2 was absent from the glands, low in stromal cells, and intense in the endothelial cells. The phase of the menstrual cycle did not appear to affect the expression of Ang-2 or Tie2 (Krikun et al., 2000) although high levels of immunohistochemical reactivity precluded a quantitative assessment of the expression of these proteins.

Most interestingly, aberrant expression of Ang-1 and 2 were shown to be associated with pathologic conditions. Recent findings suggest that LTPOC-induced endometrial bleeding occurs as a result of hypoxia/reperfusion induced free radicals that directly damage vessels and alter the balance of Ang-1 and 2 to produce the characteristic enlarged, and permeable vessels that are prone to bleeding. In vitro studies utilizing isolated human endometrial endothelial cells (HEECs), the most relevant model for endometrial microvascular biology studies, demonstrated that both hypoxia and the inflammatory agent phorbol-myristate-acetate, enhanced Ang-2 mRNA levels in HEECs suggesting that Ang-2 plays a role in endometrial pathologies complicated by impaired blood flow and inflammation. (Krikun et al., 2000).

LTPOC exposed endometrium displayed focal, intermittent staining for Ang-1 in the stroma with some areas of high staining and some areas of low to no staining. Hickey et al. (2000) have shown a trend towards reduced endometrial perfusion in LTPOC users suggestive of localized tissue hypoxia. Tissue hypoxia is almost invariably followed by re-perfusion-induced free radical damage. We hypothesized that the patchy Ang-1 endometrial staining following LTPOC was a result of focal hypoxia-reperfusion in these tissues. Consistent with this hypothesis we showed that both hypoxia and oxygen radical production decreased expression of Ang-
Angiogenesis, long term progestins and the endometrium

1 mRNA and protein in cultured HESCs (Krikun et al., 2002). In addition, it was shown that tissues derived from LTPOC treated women displayed enhanced phosphorylation of the stress activated MAP kinases, suggestive of hypoxia and oxidative damage (Krikun et al., 2002). Focal areas of hypoxia may also help to explain the discrepancies observed in VEGF expression following LTPOC use. Hence, only focal areas exposed to hypoxia would result in focal VEGF induction.

These findings suggest that aberrant angiogenesis and AUB in LTPOC-users may occur due to the dysregulated expression of the key angiogenic factors Ang-1 and Ang-2 in concert with VEGF expression.

**Tissue factor expression following LTPOC**

In addition to the effects from the classic angiogenic agents described above, studies from our laboratory have suggested that tissue factor (TF), the key initiator of the hemostatic cascade, may be involved in aberrant angiogenesis following LTPOC. TF is a 46 kDa cell membrane-bound glycoprotein resembling the members of the class 2 cytokine receptor family. It is comprised of a hydrophilic extracellular domain, a hydrophobic transmembrane domain, and a cytoplasmic domain (Guha et al., 1986; Bach, 1988; Nemerson, 1988). TF is located on the surface of several cell types including monocytes, smooth muscle cells, fibroblasts and keratinocytes and endometrial stromal cells (Lockwood et al., 1993a; Pendurthi and Rao, 2002; O'Reilly et al., 2003). By contrast, under physiological conditions, TF is absent in cells which are in contact with blood such as the endothelium. Its expression however, can be induced in these cells by inflammation, thrombin and angiogenic agents such as VEGF (Pendurthi and Rao, 2002; O'Reilly et al., 2003; Stenina, 2003). Following vascular disruption, perivascular cell-bound TF binds to plasma-derived factor VII or its activated form, FVIIa, to directly activate factor X. Factor Xa complexes with its cofactor Va, to generate thrombin (Bach, 1988; Nemerson, 1988). Cytokines, growth factors, and serum transiently (1-4 hours) induce TF mRNA, and protein in cultured cells from diverse tissues (Donovan-Peluso et al., 1994; Moll et al., 1995; Cui et al., 1996). By contrast, studies in our laboratory found that *in-vivo* and *in-vitro* decidualization of human endometrial stromal cells was associated with chronically enhanced TF protein and mRNA expression (Lockwood et al., 1993b, 2001). Moreover, enhanced TF expression required progesterone receptors and mediation by the epidermal growth factor receptor (Lockwood et al., 2000).

In addition to hemostasis, TF is now known to mediate tumor invasion, sepsis, inflammation, atherosclerosis and angiogenesis (Ruf and Mueller, 1996; Shoji et al., 1998). The interaction of TF-FVIIa elicits a variety of intracellular signaling events that may be implicated in these processes and include the sequential activation of Src-like kinases, MAP kinases, protein kinase C, PI3-kinase and calcium signaling (Versteeg et al., 2001; Peppelenbosch and Versteeg, 2001). Additionally, the angiogenic role of TF may be mediated by generating thrombin, which binds to and cleaves the endothelial cell thrombin receptor (PAR-1) (Tsopanoglou and Maragoudakis, 1999; Browder et al., 2000) to directly promote human endometrial endothelial cell mitosis (Senger et al., 1996). Moreover, thrombin itself has been shown to be angiogenic and capable of activating pro-angiogenic proteases (Senger et al., 1996). Interestingly, thrombin has also been shown to induce the expression of the VEGF receptors KDR and Flt-1 in endothelial cells (Maragoudakis et al., 2002).

In apparent contradiction with the classical role of TF as the primary initiator of hemostasis, 12 months of Norplant treatment resulted in enhanced TF expression at bleeding sites which also displayed enlarged, distended vessels (Runic et al., 2000). These effects could reflect various signaling mechanisms by TF including indirect signaling by thrombin. Indeed, as mentioned above, studies from our laboratory showed that excess thrombin resulted in the induced expression of VEGF following MPA treatment of human endometrial stromal cells (Lockwood et al., 2002).

We hypothesize that pathological angiogenesis and AUB following LTPOC is in part mediated by the interaction of TF-FVIIa resulting in intracellular signaling cascades or indirectly resulting in signaling via the production of thrombin.

**Conclusions**

For the sake of simplicity, the mechanisms proposed to account for the onset of AUB and enhanced microvessel fragility observed after LTPOC treatment have been treated as independent events. However, several of the pathways are likely to occur in concert and thus be interdependent. This could arise for related reasons, including reduced blood flow resulting in local hypoxia and reperfusion injury in turn creating an inflammatory, pro-thrombotic, pro-angiogenic environment. This could in turn create a feed-forward loop to further induce the aberrant expression and activation of molecules and pathways leading to fragile, distended vessels that are prone to bleed.

**References**


Angiogenesis, long term progestins and the endometrium


up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. 274, 15732-15739.


Accepted July 10, 2003